ARROWHEAD PHARMACEUTICALS, INC.
ARWR · XNASCIK 879407fmd_0KRCD6WJ3FM54HP07M7AVGK4YJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2002 to Sep 30, 2026, 73 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 31 | 16 | 169 | 88 | 138 | 243 | 241 | 4 | 829 | 451 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | 0 | 2 | (4) | 0 | (0) | 0 | (0) |
| Research and development | 51 | 53 | 81 | 129 | 206 | 297 | 353 | 506 | 607 | 739 |
| Selling, general and administrative | – | – | – | – | – | – | – | 99 | 124 | 202 |
| Compensation and benefits | 17 | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 68 | 72 | 108 | 181 | 287 | 422 | 446 | 605 | 731 | 1,158 |
| Operating income | (37) | (56) | 61 | (93) | (149) | (179) | (205) | (601) | 98 | (707) |
| Interest expense | – | – | – | – | 0 | 0 | 18 | 32 | 89 | 94 |
| Interest and investment income | – | – | – | – | 6 | 5 | 15 | 23 | 37 | 58 |
| Other non-operating income (expense) | 3 | 1 | 7 | 9 | 8 | 6 | (1) | (11) | (47) | (17) |
| Income before taxes | (34) | (54) | 68 | (85) | (141) | (173) | (206) | (612) | 52 | (724) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 4 | 3 | (3) | 21 | (7) |
| Net income from continuing operations | (34) | (54) | 68 | (85) | (141) | (176) | (209) | (610) | 30 | (717) |
| Net income | (34) | (54) | 68 | (85) | (141) | (176) | (205) | (599) | (2) | (724) |